glycogen synthase kinase-3beta inhibitors (Johnson & Johnson)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Nameglycogen synthase kinase-3beta inhibitors (Johnson & Johnson)
Drug Alias Nameprotein kinase C beta inhibitors (J&J)PKC-beta inhibitors (J&J)GSK-3beta inhibitors (J&J)JNJ-10164830JNJ-10184655
ClassificationSmall molecules
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitorsProtein kinase C beta inhibitors
TargetsProtein kinase C betaGlycogen synthase kinase-3 beta
Therapy Area/IndicationsCardiovascular Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A